EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, SANA: Sana Biotechnology Inc

13 Feb 26 17:33
LAST:

3.850

CHANGE:
 0.06		OPEN:
3.850		HIGH:
3.980		ASK:
0.000		VOLUME:
1.5M
CHG(%):
1.58		PREV:
3.790		LOW:
3.800		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
13 Feb 263.8503.9803.8003.8501.5M
12 Feb 263.9203.9403.7203.7901.66M
11 Feb 263.8903.9403.7203.8801.72M
10 Feb 264.0404.0953.8303.8601.77M
09 Feb 263.9004.0303.8204.0002.06M
06 Feb 263.6903.9953.6853.9303.27M
05 Feb 264.0004.0703.5303.5503.61M
04 Feb 264.4104.4204.0554.0702.67M
03 Feb 264.5904.6914.2404.4101.64M
02 Feb 264.3704.6504.2704.5901.85M

PROFILE

Name:Sana Biotechnology Inc
About:Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline consist of UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SC291, a HIP-modified allogeneic CD19-dirtected allogeneic CAR T cell product candidate which is in phase 1 clinical trial to treat systemic lupus erythematosus and ANCA-associated vasculitis, as well as in preclinical trial to treat other indications and b-cell mediated autoimmune disease; and SG299, a CD8-targeted fusosome, which is in preclinical trial to treat patients with hematologic malignancies and B cell mediated autoimmune diseases. It also develops SC262, a hypoimmune-modified CD22-directed allogeneic CAR T program, which is in phase 1 to treat non-Hodgkin's lymphoma; and SG299, a CD8-targeted fusosome, which is in preclinical trial to treat patients with hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
Sector:Healthcare
Industry:Biotechnology
Address:188 East Blaine Street, Seattle, WA, United States, 98102
Website:https://www.sana.com
CUSIP:799566104
CIK:0001770121
ISIN:US7995661045
FIGI:BBG00N5BMH61

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-3.94 
Forward P/E:-8.36 
PEG Ratio:-0.05 
Price to Book:6.35 
Return on Assets:-0.26 
Return on Equity:-1.09 
EPS Ratio:-0.96 
Shares:266.37M 
Market Cap:1.026B 

TECHNICAL INDICATORS

MA5:3.880.7%
MA10:3.993.7%
MA20:4.3613.2%
MA50:4.5017.0%
MA100:4.3914.1%
MA200:3.733.1%
STO9:26.29
STO14:18.18 
RSI14:32.96 
WPR14:-78.87
MTM14:-1.12
ROC14:-0.23 
ATR:0.32 
Week High:4.106.4%
Week Low:3.694.5%
Month High:5.2035.1%
Month Low:3.533.1%
Year High:6.5570.1%
Year Low:1.26205.6%
Volatility:11.75